Breast cancer patients’ experiences and outcomes of mainstream genetic testing with and without genetic counseling Authors: Catherine Beard, Katrina Monohan, Nitzan Lang, Linda Cicciarelli, Paul A. James, Laura E. Forrest Published: 2026 ABSTRACT ABSTRACTBackgroundAs demand for breast cancer germline testing has increased, mainstream genetic testing models of care have been implemented to increase access to genetic testing. This study examined patients’ experiences of mainstream genetic testing and compared outcomes between patients seen only by their breast specialist and those who also received genetic counseling.Patients and methodsA mixed methods approach using a survey and qualitative interviews examined decision-making, adaption to result, and family communication. Outcomes were compared by receipt of genetic counseling or not. Qualitative data were analyzed deductively.ResultsSixty-eight participants completed the survey and 20 were interviewed. Most appreciated the mainstream pathway due to an existing relationship with their cancer specialist and avoidance of extra appointments. There were no differences between those who received genetic counseling compared to those who did not regarding decision regret, cancer risk perception, or adaptation to their genetic test result. Participants who had genetic counseling had higher knowledge scores likely due to the lasting impact of their positive genetic test result.ConclusionPatients preferred the mainstream model of care, however, genetic counselor involvement was valued by those who received a pathogenic variant due to receiving counseling about the familial implications of their genetic diagnosis. Introduction Demand for cancer genetics services or familial cancer centers (FCCs) in Australia has been steadily increasing [1,2] due to raised community awareness about hereditary cancer, cancer treatment implications for individuals with germline pathogenic variants, and broadening eligibility criteria for publicly funded genetic testing [2–4]. This landscape provided impetus for the implementation of a mainstream model of care, whereby patients diagnosed with cancer undergo genetic testing with their cancer specialist during existing medical appointments. This model differs to the traditional approach where patients were referred to an FCC for genetic testing facilitated by genetic health professionals. The mainstream pathway allows for both timely access to genetic test results [5], and a more informative and tailored treatment discussion [6]. Mainstreaming programs were first established in the United Kingdom (UK) for patients with high-grade epithelial ovarian cancer [5,7]; studies demonstrate that patients are accepting of the mainstream pathway [5,8]. Mainstreaming in the breast cancer setting is still emerging, due to challenges around guidelines for genetic testing [9,10], and larger multi-disciplinary teams of breast specialists to engage and train in mainstreaming practices. Nevertheless, there is interest in universally offering genetic testing to all patients with breast cancer [3]. This highlights the importance of consolidating evidence of improved patient outcomes after mainstream genetic testing, and the need to examine clinician and patients’ experiences of breast mainstreaming. The Parkville Familial Cancer Centre (PFCC) breast cancer mainstream program has operated for 9 years in Victoria, Australia [11], with over 600 patients having undergone mainstream testing by 2024. The program involves eligible breast cancer patients undergoing mainstream genetic testing with their breast specialist. The PFCC oversees the mainstream tests, and those with pathogenic/likely pathogenic variants, and/or a significant family history of cancer are offered a genetic counseling appointment after their mainstream genetic test results are available. Further details about the operation of the PFCC breast mainstream program have been published [11]. In evaluating the PFCC breast mainstream program, three studies have taken place; an audit of program outcomes [11], a cross-sectional quantitative survey exploring the mainstream clinician experience [12], and a mixed-methods study exploring patient experiences; the latter of which is presented here and provides vital data on how breast cancer patients’ experience mainstream testing. Patients and methods A sequential mixed-method research design was adopted consisting of an online cross-sectional survey and qualitative interviews to examine patients’ psychosocial and clinical outcomes, as well as their experiences of mainstream genetic testing [13,14]. The study approved by the Peter MacCallum Cancer Centre Human Research Ethics Committee (HREC LNR/52472/PMCC-2019). Setting and sample population Men and women who had genetic testing facilitated by their cancer specialist through the PFCC breast cancer mainstream program were eligible to participate. By 24 February 2020, 275 patients had genetic testing through this program since its establishment in 2017. All patients who have mainstream genetic testing are registered in the PFCC clinical genetics database. Patients were excluded if they required an interpreter to facilitate their mainstream genetic testing or had died since receiving their results. Eligible potential participants were identified via the PFCC clinical genetics database and invited via e-mail or mail, with each invitation containing a unique URL to the online study information and survey. Data collection After providing consent, participants accessed an online survey hosted using REDCap at the Peter MacCallum Cancer Centre [15,16]. The survey consisted of seven sections: Socio-demographicsExperience of mainstream genetic testingDecision-making about genetic testingCancer risk perception and cancer worryImpact of genetic testingPsychological adaptationFamily communication Socio-demographics Socio-demographics Experience of mainstream genetic testing Experience of mainstream genetic testing Decision-making about genetic testing Decision-making about genetic testing Cancer risk perception and cancer worry Cancer risk perception and cancer worry Impact of genetic testing Impact of genetic testing Psychological adaptation Psychological adaptation Family communication Family communication Survey design The design of the survey included purpose-designed questions and Patient Reported Outcome Measures (PROMs; See supplementary material table S1). Sociodemographic variables including age, number and gender of children, partner status, level of education, postcode, and household income were collected. Experience of mainstream genetic testing was assessed using nine purpose-designed questions about satisfaction with the timing of when genetic testing was offered, the amount of information provided, which health professional the participant would have preferred to have offered genetic testing. Decision-making about genetic testing was assessed using the Decision Regret Scale [17], breast cancer risk perception was assessed using an affective and a cognitive measure [18,19], cancer worry was assessed using the Cancer Worry Scale [20], the impact of genetic testing was assessed using the Multidimensional Impact of Cancer Risk Assessment [21], and adaptation to the genetic test result was assessed using the Psychological Adaptation Scale (PAS) [22]. Family communication was examined using questions asking whether participants had informed any family members and then asking which family members they had informed using multiple-choice scenarios. Interviews After completion of the survey, a subset of purposively sampled participants were interviewed via telephone (by authors NL, KM, and CB). Recruitment ceased after reaching requisite informational power to answer the research questions. Interviews were guided by a semi-structured schedule that covered the participants’ experience of the processes involved in the mainstreaming program, including consenting to genetic testing, receiving their genetic test results, contact from the PFCC, experience of genetic counseling (if relevant) and family communication. Interviews were audio recorded and transcribed verbatim. Transcripts were quality controlled, de-identified, and pseudonyms assigned before analysis. Data analysis Quantitative analysis De-identified information about responders and non-responders were compared using X2 to determine whether there were any differences by test result or genetic counseling by the PFCC. Participants were characterized according to demographics, test result, and uptake of genetic counseling by the PFCC, and the outcome variables were tabulated to compare participants who did and did not receive genetic counseling. Descriptive statistics were generated for each PROM for patients who did and did not receive genetic counseling and compared using independent samples t-tests. In the absence of evidence-based guidelines for the interpretation of between-group differences in the CWS and risk perception scales, the Cohen’s d effect size was calculated to characterize the size of observed differences (small = 0.2; medium = 0.5; and large = 0.8). Responses to the CWS scale were dichotomized into low (≤13) and high cancer worry (≥14) and groups were compared using chi-squared testing. Multiple linear regression models were used to examine predictors of cancer worry and perceived cancer risk for patients who did and did not receive genetic counseling. The MICRA total and subscales were scored according to Cella et al. [21] and the PAS scored according to Biesecker et al. [22]. Data were analyzed using Stata IC version 14 and p values < 0.05 were considered statistically significant. Qualitative analysis Deductive content analysis was adopted to analyze the interview transcripts and assist in contextualizing the findings from the survey [23,24]. A codebook was developed using the concepts defined by the PROMs, and investigators independently coded interview transcripts into categories. QSR International NVivo v12.6.0 software (Massachusetts, USA) supported data management and analysis. Participant quotes are used to illustrate the findings with a pseudonym, age at breast cancer diagnosis in years, the germline test result, and whether or not the participant had genetic counseling in parentheses. Results Two hundred and sixty-one patients were invited (56 by e-mail and 205 via mail) and during follow-up 34 were identified as not eligible, resulting in 227 patients meeting the eligibility criteria for recruitment. Ultimately, 68 patients responded to the survey (30% response rate) between November 2020 and November 2021. Forty-one participants indicated they were willing to be interviewed, and 20 interviews were conducted with nine participants who had genetic counseling after receipt of their mainstream test result and 11 who did not. No statistical differences were observed between survey respondents who had received genetic counseling and those who had not in terms of age, sex, relationship status, education, income, and whether participants had children (Table 1). The mean age of survey respondents was 48.4 years, with a median age of 50 years (ranging from 20 to 86 years).Table 1.Participant demographics. Had genetic counselingn = 15No genetic counselingn = 53Totaln = 68p valueInterviews n = 20Age (mean, standard deviation)49.6 (42.3)48.1 (12.5)48.4 (12.5)0.749.4 (14.1) n (%)n (%)n (%) n (%)Sex (female)14 (93.3)51 (96.2)65 (95. 6)0.619 (95%)Partnered (yes)12 (80.0)40 (75.5)52 (76.5)0.715 (75)Children (yes)2 (13.3)16 (30.2)18 (26.5)0.214 (70)Tertiary education (yes)8 (53.3)26 (49.1)34 (50.0)0.119 (95)Income (≥$90k)9 (60.0)29 (54.7)38 (55.9)0.19 (50)Genetic test resultPathogenic variant (PV)7 (46.7)0 (0)7 (10.3) 4 (20%)Variant of uncertain significance (VUS)3 (20.0)0 (0)3 (4.4)3 (15%)Negative5 (33.3)53 (100)58 (85.3)13 (65%)Abbreviations: PV: pathogenic variant; VUS: variant of uncertain significance. Table 1.Participant demographics. Had genetic counselingn = 15No genetic counselingn = 53Totaln = 68p valueInterviews n = 20Age (mean, standard deviation)49.6 (42.3)48.1 (12.5)48.4 (12.5)0.749.4 (14.1) n (%)n (%)n (%) n (%)Sex (female)14 (93.3)51 (96.2)65 (95. 6)0.619 (95%)Partnered (yes)12 (80.0)40 (75.5)52 (76.5)0.715 (75)Children (yes)2 (13.3)16 (30.2)18 (26.5)0.214 (70)Tertiary education (yes)8 (53.3)26 (49.1)34 (50.0)0.119 (95)Income (≥$90k)9 (60.0)29 (54.7)38 (55.9)0.19 (50)Genetic test resultPathogenic variant (PV)7 (46.7)0 (0)7 (10.3) 4 (20%)Variant of uncertain significance (VUS)3 (20.0)0 (0)3 (4.4)3 (15%)Negative5 (33.3)53 (100)58 (85.3)13 (65%)Abbreviations: PV: pathogenic variant; VUS: variant of uncertain significance. Participant demographics. Abbreviations: PV: pathogenic variant; VUS: variant of uncertain significance. The majority of participants were offered mainstream genetic testing by a medical oncologist (55.4%), followed by breast surgeons (40%), radiation oncologists (3.1%) and breast care nurses (1.5%). Participants’ preference of who they would have liked to offer them genetic testing included 33 (50.8%) preferring a medical oncologist, 23 (35.4%) preferring a breast surgeon, two (3.1%) preferring a radiation oncologist, two (3.1%) preferring a genetic counselor, one (1.5%) preferring a breast care nurse, one (1.5%) preferring a clinical geneticist, one (1.5%) preferring a GP and two (3.1%) having no preference. Participants’ relationship with their cancer specialist played an important role in their cancer treatment. Participants were happy to have undergone the mainstream genetic testing pathway when the traditional FCC genetic testing model of care was explained during their interview, mostly due to an existing relationship with their cancer specialist, not wanting to engage with new health professionals and to avoid perceived unnecessary extra appointments. “I have a very good relationship [with medical oncologist] … very easy to talk to her… she’s always supportive … I’d rather go the way that I did because of the relationship I had with the oncologist. Bringing in another health professional … would muddy the waters for me, I trust my oncologist and I’m happy with her information. Rose (age 44 and 58 for second breast cancer, negative, no genetic counseling) “I have a very good relationship [with medical oncologist] … very easy to talk to her… she’s always supportive … I’d rather go the way that I did because of the relationship I had with the oncologist. Bringing in another health professional … would muddy the waters for me, I trust my oncologist and I’m happy with her information. Rose (age 44 and 58 for second breast cancer, negative, no genetic counseling) Overall, 63 (96.9%) were satisfied with the timing of their mainstream genetic test; 13 (20%) participants reported being offered testing at the time of their breast cancer diagnosis, 27 (41.5%) before starting their cancer treatment, 12 (18.5%) during their treatment, seven (10.8%) after treatment finished, and six (9.2%) could not remember. When the breast specialist organized genetic testing, most participants recalled receiving information via a verbal conversation (88.2%), almost half (45.6%) recalled receiving an information sheet, one participant (1.5%) was provided a weblink, and two participants (2.9%) reported no information was provided at the time of testing. Most participants were satisfied with the amount of information provided to them by their breast specialist when genetic testing was arranged (93.9%), with two participants (3.1%) wanting more information, one participant (1.5%) wanting less information and one (1.5%) with no preference. Knowledge and decision making about genetic testing Participants who had genetic counseling were more likely to demonstrate good knowledge (Table 2). Most participants did not regret their decision to undergo mainstream genetic testing, and this was consistent regardless of whether participants received genetic counseling or not.Table 2.Genetics knowledge and decision regret. Genetic counselingN (%)No genetic counselingN (%)TotalN (%)p valueKnowledgen = 15n = 53n = 68 Good knowledge11 (73.3)15 (33.3)26 (43.3)χ2 = 7.3;p = 0.01Poor knowledge4 (26.7)30 (66.7)34 (56.7)Decision regretn = 15n = 45n = 60 Range20–5515–7015–70t = 1.2p = 0.2Median (IQR)40 (35, 40)40 (40, 40)40 (40, 40)Mean (SD)38.7 (6.9)41.6 (8.4)40.8 (8.1)Abbreviations: SD: standard deviation; IQR: interquartile range. Table 2.Genetics knowledge and decision regret. Genetic counselingN (%)No genetic counselingN (%)TotalN (%)p valueKnowledgen = 15n = 53n = 68 Good knowledge11 (73.3)15 (33.3)26 (43.3)χ2 = 7.3;p = 0.01Poor knowledge4 (26.7)30 (66.7)34 (56.7)Decision regretn = 15n = 45n = 60 Range20–5515–7015–70t = 1.2p = 0.2Median (IQR)40 (35, 40)40 (40, 40)40 (40, 40)Mean (SD)38.7 (6.9)41.6 (8.4)40.8 (8.1)Abbreviations: SD: standard deviation; IQR: interquartile range. Genetics knowledge and decision regret. Abbreviations: SD: standard deviation; IQR: interquartile range. Participants described receiving sufficient information prior to having mainstream genetic testing. I was very happy…with the information that I received before having the testing, I feel like…everything was well explained to me, I knew what I was doing beforehand. Frances (age 58, BRCA2 VUS, had genetic counseling) I was very happy…with the information that I received before having the testing, I feel like…everything was well explained to me, I knew what I was doing beforehand. Frances (age 58, BRCA2 VUS, had genetic counseling) In the context of having a breast cancer diagnosis, with the whirlwind of cancer treatment coupled with the potential for genetic testing to inform treatment, participants reported not thinking too much before deciding to undergo genetic testing. I remember giving verbal consent pretty much straight away…it was a no-brainer for me. Maddy (age 31, negative, no genetic counseling) I remember giving verbal consent pretty much straight away…it was a no-brainer for me. Maddy (age 31, negative, no genetic counseling) Looking back at their decision to undergo genetic testing, many participants reported feeling like it was the right thing to do, and so retrospectively were still in support of the decision they made. This may have been due to the relief they described feeling after receiving their test result. Of the few participants who received a positive result, understanding the etiology of their cancer diagnosis was a valued part of the process. I think when it [BRCA2] was mentioned…I had never heard of it before, it was the fact that it explained how I got it [breast cancer], where it came from…it was sort of a nice feeling to know how it happened. Derek (age 68, BRCA2 PV, had genetic counseling) I think when it [BRCA2] was mentioned…I had never heard of it before, it was the fact that it explained how I got it [breast cancer], where it came from…it was sort of a nice feeling to know how it happened. Derek (age 68, BRCA2 PV, had genetic counseling) The majority of patients who received a negative genetic test result described their relief. …absolute huge relief, especially after everything that you go through with breast cancer and treatment…it’s a nice feeling…good news. Jessica (age 56, negative, no genetic counseling) …absolute huge relief, especially after everything that you go through with breast cancer and treatment…it’s a nice feeling…good news. Jessica (age 56, negative, no genetic counseling) Breast cancer risk perception and cancer worry There were no observed differences in risk perception or cancer worry amidst those who underwent genetic counseling and those who did not (Table 3).Table 3.Cancer risk perception and cancer worry scale. Had genetic counselingn = 15No genetic counselingn = 45Totaln = 60p valuePerceived chance of developing breast cancer againRange0–1000–1000–100t = 1.4p = 0.2Median (IQR)25 (6, 60)50 (20, 70)33 (17, 69.5)Mean (SD)32.7 (30.8)46.1 (31.2)42.7 (31.4)Cancer worryRange11–308–318–31t = 0.3p = 0.2Median (IQR)14 (12, 19)16 (12, 21)15.5 (12, 20)Mean (SD)16.3 (5.4)16.8 (5.4)16.7 (5.4)Abbreviations: SD: standard deviation; IQR: interquartile range. Table 3.Cancer risk perception and cancer worry scale. Had genetic counselingn = 15No genetic counselingn = 45Totaln = 60p valuePerceived chance of developing breast cancer againRange0–1000–1000–100t = 1.4p = 0.2Median (IQR)25 (6, 60)50 (20, 70)33 (17, 69.5)Mean (SD)32.7 (30.8)46.1 (31.2)42.7 (31.4)Cancer worryRange11–308–318–31t = 0.3p = 0.2Median (IQR)14 (12, 19)16 (12, 21)15.5 (12, 20)Mean (SD)16.3 (5.4)16.8 (5.4)16.7 (5.4)Abbreviations: SD: standard deviation; IQR: interquartile range. Cancer risk perception and cancer worry scale. Abbreviations: SD: standard deviation; IQR: interquartile range. With the shock and chaos of a cancer diagnosis, anxiety was commonly reported by interviewees. One participant who had had two primary breast cancer diagnoses 14 years apart reflected on the persistent cancer anxiety she experienced after her first diagnosis: It is at the back of your mind every day and there is nothing you can do to escape that … Most days you just move on but other days, when something happens … you think ‘oh is this something?’ Rose (age 44 and 58 for second breast cancer, negative, no genetic counseling) It is at the back of your mind every day and there is nothing you can do to escape that … Most days you just move on but other days, when something happens … you think ‘oh is this something?’ Rose (age 44 and 58 for second breast cancer, negative, no genetic counseling) For some participants, cancer anxiety led to a desire for preventative surgery receiving their breast cancer diagnosis. I knew at that point, I just did not want … ovaries that could turn to cancer, or anything else. And I just wanted everything out. Annie (age 34, negative, no genetic counseling) I knew at that point, I just did not want … ovaries that could turn to cancer, or anything else. And I just wanted everything out. Annie (age 34, negative, no genetic counseling) Having the mainstream test did not appear to increase participant worry beyond that related to their cancer diagnosis, with many participants describing feeling like the mainstream test was no more significant than any other of the tests associated with their cancer treatment. To me it was just a test, another test, it didn’t really have [an] impact on me. Matilda (age 34, negative, no genetic counseling) To me it was just a test, another test, it didn’t really have [an] impact on me. Matilda (age 34, negative, no genetic counseling) Impact of genetic test result and adaptation to genetic information There were no observed differences between participants who underwent genetic counseling and those who did not in terms of the impact of the genetic test result and adaptation to the genetic test result (Table 4).Table 4.Impact of genetic test result and adaptation to genetic information. Had genetic counselingn = 14No genetic counselingn = 45Totaln = 59p valueImpact of genetic test result: MICRA totalRange6–500–490–500.45Mean (SD)20.2 (13.5)17.3 (12.2)18.0 (12.5)Impact of genetic test result: MICRA distressRange0–280–160–280.17Mean (SD)4.6 (8.2)2.3 (4.3)2.9 (5.5)Impact of genetic test result: MICRA uncertaintyRange0–240–300–300.91Mean (SD)6.8 (5.6)7.0 (7.2)7.0 (6.8)Impact of genetic test result: MICRA positive experienceRange0–200–200–200.71Mean (SD)8.8 (6.7)8.0 (7.3)8.2 (7.1)AdaptationRange15–7515–7515–750.32Mean (SD)49.1 (20.0)42.6 (21.7)44.2 (21.3)Abbreviations: SD: standard deviation. Table 4.Impact of genetic test result and adaptation to genetic information. Had genetic counselingn = 14No genetic counselingn = 45Totaln = 59p valueImpact of genetic test result: MICRA totalRange6–500–490–500.45Mean (SD)20.2 (13.5)17.3 (12.2)18.0 (12.5)Impact of genetic test result: MICRA distressRange0–280–160–280.17Mean (SD)4.6 (8.2)2.3 (4.3)2.9 (5.5)Impact of genetic test result: MICRA uncertaintyRange0–240–300–300.91Mean (SD)6.8 (5.6)7.0 (7.2)7.0 (6.8)Impact of genetic test result: MICRA positive experienceRange0–200–200–200.71Mean (SD)8.8 (6.7)8.0 (7.3)8.2 (7.1)AdaptationRange15–7515–7515–750.32Mean (SD)49.1 (20.0)42.6 (21.7)44.2 (21.3)Abbreviations: SD: standard deviation. Impact of genetic test result and adaptation to genetic information. Abbreviations: SD: standard deviation. One participant described feeling her treatment decision was validated by her genetic test result, which she received immediately prior to undergoing bilateral mastectomy. …when I got my diagnosis…I decided I was going to have a double bilateral radical mastectomy. I pretty much argued with the [doctor]. I was like, it’s happening my way or it’s not happening at all… basically when I was in theatre…they were like…you’re BRCA2 positive. And I closed my eyes going, I made the absolute right decision, I’m really happy. Lucy (age 30, BRCA2 PV, had genetic counseling) …when I got my diagnosis…I decided I was going to have a double bilateral radical mastectomy. I pretty much argued with the [doctor]. I was like, it’s happening my way or it’s not happening at all… basically when I was in theatre…they were like…you’re BRCA2 positive. And I closed my eyes going, I made the absolute right decision, I’m really happy. Lucy (age 30, BRCA2 PV, had genetic counseling) In processing their genetic test result, participants who had genetic counseling valued the information, time, and space afforded to them by the genetic counselor to assist in this process. … [they] gave me a wealth of information … [they were] so lovely and I do remember being very grateful that [they] had time to spend with me. Frances (age 58, BRCA2 VUS, had genetic counseling) … [they] gave me a wealth of information … [they were] so lovely and I do remember being very grateful that [they] had time to spend with me. Frances (age 58, BRCA2 VUS, had genetic counseling) Family communication Most participants had informed family members about their genetic test results (91.5%), and this was similarly reported for both those who underwent genetic counseling and those who did not (p = 0.8). All participants who underwent genetic counseling reported informing at least close relatives, whereas participants who did not have genetic counseling (all of whom had negative genetic test results) seemed to be more varied in who they had told (Table 5).Table 5.Family members reportedly informed about participants’ genetic test result. Had genetic counselingn = 13No genetic counselingn = 41Totaln = 54“I’ve told those most likely to be impacted (e.g., sisters, daughters)”0 (0%)10 (24.4%)10 (18.5%)“I’ve told some or all of my close (blood) relatives”8 (61.5%)17 (41.5%)25 (46.3%)“I’ve told my close relatives and some extended relatives”5 (38.5%)14 (34.1%)19 (35.2%) Table 5.Family members reportedly informed about participants’ genetic test result. Had genetic counselingn = 13No genetic counselingn = 41Totaln = 54“I’ve told those most likely to be impacted (e.g., sisters, daughters)”0 (0%)10 (24.4%)10 (18.5%)“I’ve told some or all of my close (blood) relatives”8 (61.5%)17 (41.5%)25 (46.3%)“I’ve told my close relatives and some extended relatives”5 (38.5%)14 (34.1%)19 (35.2%) Family members reportedly informed about participants’ genetic test result. Participants described feeling motivated to inform family members of genetic testing. Some participants spoke with family about their genetic test, whilst trying to gather details about their family history of cancer. I was … starting to talk to parents and grandparents about, what’s your history? …Who, if anyone, has had a history of cancer or breast cancer and kind of highlighting how murky our family history is…yeah, it often starts those…family conversations … Zoe (age 34, BRCA1 VUS, had genetic counseling) I was … starting to talk to parents and grandparents about, what’s your history? …Who, if anyone, has had a history of cancer or breast cancer and kind of highlighting how murky our family history is…yeah, it often starts those…family conversations … Zoe (age 34, BRCA1 VUS, had genetic counseling) For those with a pathogenic variant, participants described wanting to inform relatives so that they could access genetic testing and described the support they received from the PFCC to assist with this. So, my uncle who got tested [interstate]…we had been told by [PFCC] that he should go [to] a hospital in [city], he should get a referral from his GP. So, [PFCC] was very helpful in trying to help him with the process but the process in [city] was a nightmare….it was really complicated. Took them months and months to get it done. Mary (age 51, BRCA1 PV, had genetic counseling) So, my uncle who got tested [interstate]…we had been told by [PFCC] that he should go [to] a hospital in [city], he should get a referral from his GP. So, [PFCC] was very helpful in trying to help him with the process but the process in [city] was a nightmare….it was really complicated. Took them months and months to get it done. Mary (age 51, BRCA1 PV, had genetic counseling) Genetic counseling was critical in supporting patients to feel prepared about communicating genetic information by understanding who their at-risk family members were and what they needed to tell them about the hereditary cancer risk. I brought it up with [my relatives] a couple of years ago….once [GC] got me on the job, I sort of got in touch with who I could get in contact with pretty quickly…Yeah so, I did, leave that meeting [with the genetic counselor] feeling that I knew everything that I needed to know to go ahead and contact my family members, could answer all their questions. Derek (age 68, BRCA2 PV, had genetic counseling) I brought it up with [my relatives] a couple of years ago….once [GC] got me on the job, I sort of got in touch with who I could get in contact with pretty quickly…Yeah so, I did, leave that meeting [with the genetic counselor] feeling that I knew everything that I needed to know to go ahead and contact my family members, could answer all their questions. Derek (age 68, BRCA2 PV, had genetic counseling) Discussion Participants in this study, who were asked to recall their experience and decision-making about genetic testing facilitated by their oncology specialist, reported they preferred this mainstream model of care rather than having genetic testing at the FCC. This preference was underpinned by the enduring relationship with their breast specialist, where the participants trusted their doctor’s reason and capability for ordering the genetic test and appreciated that it negated the need to see another health professional as part of their care continuum. This is similar to preferences reported by patients who had treatment focused genetic testing (TFGT) who preferred their oncology specialist offer this testing rather than a genetics specialist within the traditional FCC model of care [5,25–28]. While participants cannot compare the two models of care to inform their preference, it is encouraging that participants in this study did not demonstrate regret about their decision to have genetic testing facilitated by their breast specialists and this aligns with findings from other studies [1,5,29–32]. Despite early concerns that the timing of genetic testing close to a cancer diagnosis might be distressing for patients [33], subsequent studies have demonstrated that genetic testing after a cancer diagnosis does not appear to increase distress [34]. In this study, no differences were observed in cancer worry or the impact of the genetic test result between those who did and did not receive genetic counseling, with the group who had genetic counseling including all those who received a positive genetic test result. This finding is similar to outcomes from the MAGIC study, where median cancer-specific distress scores were similar amongst those who had positive and negative genetic test results [1]. Indeed, the support expressed by participants indicating they were comfortable with genetic testing being offered close to the time of their breast cancer diagnosis and speaks to the successful incorporation of genetic testing in cancer care [26,28,32,35]. The move from the traditional FCC-led approach for genetic testing to the mainstream model was initially implemented cautiously due to concerns that a lack of genetic counseling may impact psychological outcomes for patients. Our study contributes to the growing evidence that patients do not experience detrimental outcomes when genetic testing is facilitated in the mainstream setting [8], and instead value the opportunity to have their testing incorporated within their cancer treatment pathway and facilitated by a trusted oncology specialist. The value of genetic counseling was instead realized by the participants in our study for whom it was most relevant: those identified with a pathogenic variant, psychosocial challenges, or high-risk family histories. This was evident from the greater knowledge scores achieved by participants who had genetic counseling and from the experiential descriptions, particularly when considering the familial implications of a genetic diagnosis. These participants described how genetic counseling helped them understand who was at risk of the hereditary cancer condition in their family and how to communicate the genetic information to them. Supporting patients’ family communication is one of the core tenets of genetic counseling process and practice due to the familial implications inherent in a genetic diagnosis [36,37]. Genetic counseling improves patient outcomes and so, as genetic testing is moved into the mainstream, it remains important that genetic counseling and genetic counselors are available to patients who receive a positive genetic test result, have a family history of cancer, or have psychosocial concerns relevant to inherited cancer risks, to benefit from psychotherapeutic counseling, and address personal and familial needs [36–38]. Limitations This study employed a retrospective approach to examine participants’ experiences of mainstream breast cancer genetic testing, which relied on recall, often years after the mainstream experience. This length of time may have impacted participants’ ability to recall the details of their genetic testing experience that was nested within an experience involving fast-paced and life-altering decisions regarding surgery, chemotherapy, and/or radiation. The small sample size for the cross-sectional survey limited the ability to reliably examine any differences experienced between those who did or did not receive genetic counseling. Further, the genetics knowledge questions asked as part of the multidimensional measure of informed choice (MMIC) may not have been appropriately suited to the participant group who tested negative as this information is not necessarily relevant and therefore retained by these individuals. Finally, as there was no comparative group that had genetic testing via the traditional FCC pathway, the preference for the mainstream pathway expressed by participants may be drawn from their assumptions that is may have introduced some burden to their care pathway if they had been referred to an FCC. Conclusions Mainstream genetic testing was preferred by participants in this study, which was facilitated by their breast specialist as another test within their cancer treatment pathway. While most received a negative test result and did not have genetic counseling, the participants for whom there was a clinical indication found the genetic counseling beneficial. Participants reported feeling informed and supported to have genetic testing facilitated by their breast specialist due to the often longitudinal and trusted relationship they developed throughout their breast cancer treatment. There was also a desire expressed by participants to not introduce new health professionals via a referral to an FCC into the already busy and complicated treatment pathway. Participants did not report any detrimental psychosocial implications after having genetic testing facilitated by their breast specialist through the mainstream model, noting that most received a negative genetic test result and did not receive any genetic counseling. The implementation of the mainstream model of care could be viewed as supporting the rationalization of health service delivery by delivering genetic counseling provided by genetic counselors to patients who needed it most due to the identification of a pathogenic variant, had psychosocial challenges, or high-risk family histories. The findings from this study suggest that this mainstream model implemented as a partnership between breast specialists working in outpatient oncology clinics with support from the FCC provided patient-centered care. The mainstream model of genetic testing introduces efficiencies into patients’ experiences of their cancer care, and when partnered with an FCC, ensures genetic counselors are available to the patients who need them most. Supplementary Material Supplemental Material